CClinicalTrials.gg
Status unknownNCT03586960Updated Jul 16, 2018

Use of a Novel Device for Stretch Relaxation During Mohs Surgery

An interventional study of Peak Force Measurement in Tissue Expander Disorder, Stress Strain Curve and Tissue Expansion, sponsored by Silver Falls Dermatology. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-16.

Sponsored by Silver Falls Dermatology · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jul 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Closure of cutaneous defects is associated with many common and serious problems. For example, Mohs surgery involves the removal of skin and other soft tissues that have been proven to be infiltrated with cancer. Iterative stages of Mohs are processed and examined microscopically for residual tumor. Using specialized mapping, the surgeon can effectively achieve a high cure rate and minimize removal of unaffected tissue. This process usually takes a total of 2-3 hours, since the patient waits while the tissue is being processed, and complete clearance of margins can take multiple stages. In many cases, a cutaneous defect is produced of significant size. In certain areas of high tension, such as scalp and lower leg, this mandates either a lengthy course of wound care or that the surgeon perform a graft or flap. In many cases, performance of a graft is undesirable due to lack of vascularity to support graft survival. Creation of flaps involves incision and undermining of large areas of tissue in order to achieve wound closure. There is a current need for alternatives to graft and flaps in these locations.

Human skin has biomechanical properties that can be harnessed to facilitate closure of larger wounds. Stress-relaxation refers to the natural relaxation exhibited by skin put under a given amount of tension (stress) over time. After a period of stress, the force required to close the wound is reduced. In a porcine skin wound model, there is a 40-60% reduction in stress after twenty minutes of stretch relaxation.

There are several classic methods of delivering this stretch to skin intraoperatively. Most simply, a towel clamp can be used to bring edges together. However, the clamp, which is a sharp stainless steel instrument, can damage tissues. There are also commercial devices such as TopClosure. However, this device is intended for very large wounds with side plates that must be sutured or stapled to patient skin.

The SUTUREGARD device presents a simple method to provide stress to a wound but not damage tissue. The SUTUREGARD device results in significantly lower pressure on the skin when compared with traditional sutures and creates a much greater volume of wound eversion than is possible with a traditional suturing method. Engineering tests performed at OSU showed that a given simple interrupted suture will exert about 30% less pressure on the skin when used performed with the device compared to without the device. With this protection, this creates the corollary that a suture could be safely tied to a greater force with the device than without. In animal testing, the device has been used on porcine wounds for up to 6 weeks, where it showed superior histologic tolerability over traditional sutures.

The investigators have used the device to provide stress-relaxation within our clinic over the past several months and have seen reductions in wound width of about 30% with retention of the device for 30-60 minutes. Wounds exhibit significantly more reduction in width with overnight use. Unlike traditional retention sutures, which damage the skin, the skin appears normal with retention of the device for up to 2 days in our patients. Furthermore, all wounds that have been stress-relaxed with the device have healed without complication.

The investigators plan to study the stress-relaxation created by use of a SUTUREGARD device applied to cutaneous defects for a specified time periods (30, 60 and 90 minutes).

02

Conditions studied

  • Tissue Expander Disorder
  • Stress Strain Curve
  • Tissue Expansion
  • Mohs Surgery
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Any wound that cannot be reapproximated upon tumor removal (These locations are often on the lower leg and scalp.)
  • Age over 18 years
  • Intact skin surrounding wound for at least 2.5 cm

Exclusion criteria

Exclusion Criteria:

  • Active infection
  • Systemically unstable or unwell patient
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.

    Device: Peak Force Measurement

Interventions

  • DevicePeak Force Measurement

    Force will be measured at 5,10, and 30 minutes

05

What researchers measure

Primary outcomes

  1. Direct measurements of wound dimensions at each timepoint

    Measurements will be taken at each time point of wound size

    Time frame: 5 minutes

  2. Direct measurements of wound dimensions at each timepoint

    Measurements will be taken at each time point of wound size

    Time frame: 10 minutes

  3. Direct measurements of wound dimensions at each timepoint

    Measurements will be taken at each time point of wound size

    Time frame: 30 minutes

06

Study locations

1 of 1 sites recruiting
  • Silver Falls Dermtology
    Salem, Oregon 97302, United States
    • Angie Tingle · Contact · atingle@silverfallsderm.net · 503-362-8385
    • William Lear, MD · Principal investigator
    • Collin M Blattner, DO · Sub investigator
    • Allie Melkonian, DO · Sub investigator
    Recruiting
07

References and documents

Publications

  • Saqib NU, Domenick N, Cho JS, Marone L, Leers S, Makaroun MS, Chaer RA. Predictors and outcomes of restenosis following tibial artery endovascular interventions for critical limb ischemia. J Vasc Surg. 2013 Mar;57(3):692-9. doi: 10.1016/j.jvs.2012.08.115. Epub 2013 Jan 23. PubMed 23351646 ↗
  • Townsend KL, Akeroyd J, Russell DS, Kruzic JJ, Robertson BL, Lear W. Comparing the Tolerability of a Novel Wound Closure Device Using a Porcine Wound Model. Adv Wound Care (New Rochelle). 2018 Jun 1;7(6):177-184. doi: 10.1089/wound.2017.0777. PubMed 29892494 ↗
  • Topaz M, Carmel NN, Topaz G, Li M, Li YZ. Stress-relaxation and tension relief system for immediate primary closure of large and huge soft tissue defects: an old-new concept: new concept for direct closure of large defects. Medicine (Baltimore). 2014 Dec;93(28):e234. doi: 10.1097/MD.0000000000000234. PubMed 25526444 ↗
  • Hussain SH, Limthongkul B, Humphreys TR. The biomechanical properties of the skin. Dermatol Surg. 2013 Feb;39(2):193-203. doi: 10.1111/dsu.12095. Epub 2013 Jan 25. PubMed 23350638 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03586960
Lead sponsor
Silver Falls Dermatology
Responsible party
Sponsor
First posted
Jul 16, 2018
Start date
Jul 2, 2018
Primary completion
Aug 31, 2018 (estimated)
Completion
Sep 30, 2018 (estimated)
Last update
Jul 16, 2018

Study contacts

Angie Tingle
Contact
atingle@silverfallsderm.net
503 362 8385

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion